ZA951470B - Agent for prophylaxis and treatment of thromboxane A2-mediated diseases - Google Patents

Agent for prophylaxis and treatment of thromboxane A2-mediated diseases

Info

Publication number
ZA951470B
ZA951470B ZA951470A ZA951470A ZA951470B ZA 951470 B ZA951470 B ZA 951470B ZA 951470 A ZA951470 A ZA 951470A ZA 951470 A ZA951470 A ZA 951470A ZA 951470 B ZA951470 B ZA 951470B
Authority
ZA
South Africa
Prior art keywords
txa2
mediated diseases
prophylaxis
pct
agent
Prior art date
Application number
ZA951470A
Other languages
English (en)
Inventor
Ruriko Ikegawa
Teruaki Imada
Norifumi Nakamura
Kaizo Tanikawa
Nobutomo Tsuruzoe
Original Assignee
Green Cross Corp
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Nissan Chemical Ind Ltd filed Critical Green Cross Corp
Publication of ZA951470B publication Critical patent/ZA951470B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
ZA951470A 1994-02-22 1995-02-22 Agent for prophylaxis and treatment of thromboxane A2-mediated diseases ZA951470B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2455694 1994-02-22

Publications (1)

Publication Number Publication Date
ZA951470B true ZA951470B (en) 1995-12-07

Family

ID=12141437

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA951470A ZA951470B (en) 1994-02-22 1995-02-22 Agent for prophylaxis and treatment of thromboxane A2-mediated diseases

Country Status (16)

Country Link
US (1) US5798357A (de)
EP (1) EP0744950B1 (de)
JP (1) JP3858279B2 (de)
KR (1) KR100345187B1 (de)
CN (1) CN1084620C (de)
AT (1) ATE273708T1 (de)
AU (1) AU1718395A (de)
CA (1) CA2183234C (de)
DE (1) DE69533392T2 (de)
DK (1) DK0744950T3 (de)
ES (1) ES2222464T3 (de)
FI (1) FI116882B (de)
IL (1) IL112695A (de)
NO (1) NO311490B1 (de)
WO (1) WO1995022329A1 (de)
ZA (1) ZA951470B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
WO1999011268A1 (en) * 1997-08-28 1999-03-11 Yoshitomi Pharmaceutical Industries, Ltd. Neovascularization promoters and neovascularization potentiators
US6143113A (en) 1998-03-02 2000-11-07 Le Groupe Recherche I.D. Inc. Repulpable corrugated boxboard
CA2342198C (en) 1998-09-01 2007-08-28 Welfide Corporation Therapeutic agent for spinal canal stenosis
CN1163230C (zh) * 1998-12-07 2004-08-25 日产化学工业株式会社 勃起功能障碍治疗剂
KR20060125816A (ko) * 2003-12-26 2006-12-06 닛산 가가쿠 고교 가부시키 가이샤 호중구증다 억제제
CA2714160A1 (en) * 2008-01-29 2009-08-06 Indigo Pharmaceuticals A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease
CN113546049B (zh) * 2021-04-30 2023-03-17 贵州汉方药业有限公司 一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599336A (en) * 1983-08-08 1986-07-08 Hoffmann-La Roche Inc. Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide
EP0142057A3 (de) * 1983-11-04 1988-03-30 F. Hoffmann-La Roche Ag Thiazolochinazolin-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zubereitungen
HU198696B (en) * 1987-01-20 1989-11-28 Nissan Chemical Ind Ltd Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
DK0482208T3 (da) * 1990-04-25 2000-09-18 Nissan Chemical Ind Ltd Pyridazinonderivat

Also Published As

Publication number Publication date
DE69533392D1 (de) 2004-09-23
NO311490B1 (no) 2001-12-03
US5798357A (en) 1998-08-25
CN1141590A (zh) 1997-01-29
CN1084620C (zh) 2002-05-15
DK0744950T3 (da) 2004-10-25
IL112695A (en) 1999-04-11
ES2222464T3 (es) 2005-02-01
ATE273708T1 (de) 2004-09-15
KR100345187B1 (ko) 2002-12-05
NO963463L (no) 1996-08-20
EP0744950B1 (de) 2004-08-18
FI963264A0 (fi) 1996-08-21
FI116882B (fi) 2006-03-31
EP0744950A1 (de) 1996-12-04
JPH07285869A (ja) 1995-10-31
FI963264A7 (fi) 1996-08-21
WO1995022329A1 (en) 1995-08-24
IL112695A0 (en) 1995-05-26
CA2183234A1 (en) 1995-08-24
AU1718395A (en) 1995-09-04
DE69533392T2 (de) 2005-09-01
CA2183234C (en) 2004-05-04
JP3858279B2 (ja) 2006-12-13
KR970701048A (ko) 1997-03-17

Similar Documents

Publication Publication Date Title
KR950702180A (ko) 류코트리엔 생합성 억제제로서의 치환된 아릴알키닐-및 헤테로아릴알키닐-N-하이드록시우레아(substituted arylalkynyl-and heteroarylalkyny-N-hydroxyurea inhibi tors of leukotriene biosynthesis)본 내용은 요부공개 건이므로 전문 내용을 수록하지 않았음
AU2267395A (en) Benzofuran derivatives useful as inhibitors of bone resorption
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY136173A (en) 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
NO2005019I2 (no) Metylaminolevulinat, eventuelt i form av et salt, fortrinnsvis metylaminolevulinat-hydroklorid
FI943948A0 (fi) Heterosykliset hiilihappojohdannaiset
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
UA35584C2 (uk) Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців
IN2005KO00312A (de)
AU4888401A (en) Sulfonamide derivative as a matrix metalloproteinase inhibitor
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
ES2098947T3 (es) Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol.
AU4923093A (en) Inhibitors of metazoan parasite proteases
ZA951470B (en) Agent for prophylaxis and treatment of thromboxane A2-mediated diseases
AU5844096A (en) Brain edema inhibitor
AU7467694A (en) Pyridazinone derivatives or their salts, processes for theirproduction, and anti-shock agents containing them
PL313037A1 (en) Phenoxphenylocyclopententenylohydroxyureas
AU5819394A (en) N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders
AU2003263455A1 (en) Pyrazole amides for treating hiv infections
WO2022132997A9 (en) Bicyclic pyrazole bruton's tyrosine kinase inhibitors
MXPA04005310A (es) Inhibidores de fosfolipasa a2 citosolica.